SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) Stock Competitors & Peer Comparison
See SWTX's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for SWTX and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| SWTX | $46.99 | +0.00% | 3.5B | -13.78 | -$3.41 | N/A |
| VRTX | $506.74 | -3.07% | 128.6B | 26.63 | $19.03 | N/A |
| REGN | $734.81 | -3.09% | 75.7B | 16.10 | $45.63 | +0.50% |
| MRNA | $188.94 | -1.89% | 75B | -23.18 | -$8.15 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $936.00 | -2.39% | 58.2B | 33.75 | $27.73 | N/A |
| RVMDW | $11.60 | +1.40% | 44.9B | -1.30 | -$8.82 | N/A |
| RVMD | $205.89 | +0.31% | 43.8B | -23.34 | -$8.82 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ONC | $358.77 | -1.96% | 38.3B | 63.16 | $5.68 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
SWTX vs VRTX Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, VRTX has a market cap of 128.6B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while VRTX trades at $506.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas VRTX's P/E ratio is 26.63. In terms of profitability, SWTX's ROE is -0.47%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, SWTX is less volatile compared to VRTX. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check VRTX's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
SWTX vs REGN Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, REGN has a market cap of 75.7B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while REGN trades at $734.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas REGN's P/E ratio is 16.10. In terms of profitability, SWTX's ROE is -0.47%, compared to REGN's ROE of +0.14%. Regarding short-term risk, SWTX is less volatile compared to REGN. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check REGN's competition here
Moderna, Inc. (NASDAQ: MRNA)
SWTX vs MRNA Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, MRNA has a market cap of 75B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while MRNA trades at $188.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas MRNA's P/E ratio is -23.18. In terms of profitability, SWTX's ROE is -0.47%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, SWTX is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check MRNA's competition here
Verona Pharma plc (NASDAQ: VRNA)
SWTX vs VRNA Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas VRNA's P/E ratio is -102.80. In terms of profitability, SWTX's ROE is -0.47%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, SWTX is similarly volatile compared to VRNA. This indicates similar risk in terms of short-term price fluctuations for SWTX.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
SWTX vs ARGX Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, ARGX has a market cap of 58.2B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while ARGX trades at $936.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas ARGX's P/E ratio is 33.75. In terms of profitability, SWTX's ROE is -0.47%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, SWTX is less volatile compared to ARGX. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check ARGX's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
SWTX vs RVMDW Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, RVMDW has a market cap of 44.9B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while RVMDW trades at $11.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas RVMDW's P/E ratio is -1.30. In terms of profitability, SWTX's ROE is -0.47%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, SWTX is less volatile compared to RVMDW. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check RVMDW's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
SWTX vs RVMD Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, RVMD has a market cap of 43.8B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while RVMD trades at $205.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas RVMD's P/E ratio is -23.34. In terms of profitability, SWTX's ROE is -0.47%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, SWTX is less volatile compared to RVMD. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check RVMD's competition here
Seagen Inc. (NASDAQ: SGEN)
SWTX vs SGEN Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas SGEN's P/E ratio is -57.19. In terms of profitability, SWTX's ROE is -0.47%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, SWTX is less volatile compared to SGEN. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check SGEN's competition here
BeOne Medicines AG (NASDAQ: ONC)
SWTX vs ONC Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, ONC has a market cap of 38.3B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while ONC trades at $358.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas ONC's P/E ratio is 63.16. In terms of profitability, SWTX's ROE is -0.47%, compared to ONC's ROE of +0.14%. Regarding short-term risk, SWTX is less volatile compared to ONC. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check ONC's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
SWTX vs ALNY Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, ALNY has a market cap of 30.9B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while ALNY trades at $231.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas ALNY's P/E ratio is 41.65. In terms of profitability, SWTX's ROE is -0.47%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, SWTX is less volatile compared to ALNY. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
SWTX vs ROIV Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, ROIV has a market cap of 25.6B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while ROIV trades at $35.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas ROIV's P/E ratio is -33.77. In terms of profitability, SWTX's ROE is -0.47%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, SWTX is less volatile compared to ROIV. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check ROIV's competition here
BioNTech SE (NASDAQ: BNTX)
SWTX vs BNTX Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, BNTX has a market cap of 24.3B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while BNTX trades at $96.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas BNTX's P/E ratio is -12.56. In terms of profitability, SWTX's ROE is -0.47%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, SWTX is less volatile compared to BNTX. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check BNTX's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
SWTX vs UTHR Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, UTHR has a market cap of 24.3B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while UTHR trades at $571.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas UTHR's P/E ratio is 20.44. In terms of profitability, SWTX's ROE is -0.47%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, SWTX is less volatile compared to UTHR. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check UTHR's competition here
Incyte Corporation (NASDAQ: INCY)
SWTX vs INCY Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, INCY has a market cap of 23.7B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while INCY trades at $117.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas INCY's P/E ratio is 15.74. In terms of profitability, SWTX's ROE is -0.47%, compared to INCY's ROE of +0.30%. Regarding short-term risk, SWTX is less volatile compared to INCY. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check INCY's competition here
Insmed Incorporated (NASDAQ: INSM)
SWTX vs INSM Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, INSM has a market cap of 23.5B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while INSM trades at $108.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas INSM's P/E ratio is -26.42. In terms of profitability, SWTX's ROE is -0.47%, compared to INSM's ROE of -1.11%. Regarding short-term risk, SWTX is less volatile compared to INSM. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check INSM's competition here
Genmab A/S (NASDAQ: GMAB)
SWTX vs GMAB Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, GMAB has a market cap of 21.9B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while GMAB trades at $34.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas GMAB's P/E ratio is 26.88. In terms of profitability, SWTX's ROE is -0.47%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, SWTX is less volatile compared to GMAB. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check GMAB's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
SWTX vs BGNE Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas BGNE's P/E ratio is -22.55. In terms of profitability, SWTX's ROE is -0.47%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, SWTX is less volatile compared to BGNE. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
SWTX vs DNA-WT Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, SWTX's ROE is -0.47%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, SWTX is less volatile compared to DNA-WT. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check DNA-WT's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
SWTX vs JAZZ Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, JAZZ has a market cap of 14.6B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while JAZZ trades at $233.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas JAZZ's P/E ratio is 8.69. In terms of profitability, SWTX's ROE is -0.47%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, SWTX is less volatile compared to JAZZ. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check JAZZ's competition here
Exelixis, Inc. (NASDAQ: EXEL)
SWTX vs EXEL Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, EXEL has a market cap of 14.6B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while EXEL trades at $57.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas EXEL's P/E ratio is 16.55. In terms of profitability, SWTX's ROE is -0.47%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, SWTX is less volatile compared to EXEL. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check EXEL's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
SWTX vs NBIX Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, NBIX has a market cap of 14.1B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while NBIX trades at $140.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas NBIX's P/E ratio is 20.33. In terms of profitability, SWTX's ROE is -0.47%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, SWTX is less volatile compared to NBIX. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check NBIX's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
SWTX vs ASND Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, ASND has a market cap of 14.1B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while ASND trades at $227.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas ASND's P/E ratio is -93.93. In terms of profitability, SWTX's ROE is -0.47%, compared to ASND's ROE of +1.90%. Regarding short-term risk, SWTX is less volatile compared to ASND. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check ASND's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
SWTX vs SMMT Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, SMMT has a market cap of 13.3B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while SMMT trades at $16.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas SMMT's P/E ratio is -14.89. In terms of profitability, SWTX's ROE is -0.47%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, SWTX is less volatile compared to SMMT. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check SMMT's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
SWTX vs BBIO Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, BBIO has a market cap of 13.1B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while BBIO trades at $66.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas BBIO's P/E ratio is -17.89. In terms of profitability, SWTX's ROE is -0.47%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, SWTX is less volatile compared to BBIO. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check BBIO's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
SWTX vs HALO Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, HALO has a market cap of 12.7B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while HALO trades at $106.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas HALO's P/E ratio is 19.95. In terms of profitability, SWTX's ROE is -0.47%, compared to HALO's ROE of +1.81%. Regarding short-term risk, SWTX is less volatile compared to HALO. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check HALO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
SWTX vs KRTX Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas KRTX's P/E ratio is -28.09. In terms of profitability, SWTX's ROE is -0.47%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, SWTX is less volatile compared to KRTX. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check KRTX's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
SWTX vs TWST Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, TWST has a market cap of 11.7B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while TWST trades at $188.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas TWST's P/E ratio is -84.71. In terms of profitability, SWTX's ROE is -0.47%, compared to TWST's ROE of -0.30%. Regarding short-term risk, SWTX is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check TWST's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
SWTX vs MDGL Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, MDGL has a market cap of 11.5B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while MDGL trades at $499.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas MDGL's P/E ratio is -39.04. In terms of profitability, SWTX's ROE is -0.47%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, SWTX is less volatile compared to MDGL. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check MDGL's competition here
Bio-Techne Corporation (NASDAQ: TECH)
SWTX vs TECH Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while TECH trades at $72.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas TECH's P/E ratio is 37.32. In terms of profitability, SWTX's ROE is -0.47%, compared to TECH's ROE of +0.09%. Regarding short-term risk, SWTX is less volatile compared to TECH. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check TECH's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
SWTX vs BMRN Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, BMRN has a market cap of 11.3B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while BMRN trades at $58.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas BMRN's P/E ratio is 28.10. In terms of profitability, SWTX's ROE is -0.47%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, SWTX is less volatile compared to BMRN. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check BMRN's competition here
10x Genomics, Inc. (NASDAQ: TXG)
SWTX vs TXG Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, TXG has a market cap of 11.3B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while TXG trades at $88.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas TXG's P/E ratio is -150.44. In terms of profitability, SWTX's ROE is -0.47%, compared to TXG's ROE of -0.09%. Regarding short-term risk, SWTX is less volatile compared to TXG. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check TXG's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
SWTX vs RNAM Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas RNAM's P/E ratio is -17.39. In terms of profitability, SWTX's ROE is -0.47%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, SWTX is similarly volatile compared to RNAM. This indicates similar risk in terms of short-term price fluctuations for SWTX.Check RNAM's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
SWTX vs IBRX Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, IBRX has a market cap of 9.7B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while IBRX trades at $9.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas IBRX's P/E ratio is -9.57. In terms of profitability, SWTX's ROE is -0.47%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, SWTX is less volatile compared to IBRX. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check IBRX's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
SWTX vs KRYS Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, KRYS has a market cap of 9.6B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while KRYS trades at $325.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas KRYS's P/E ratio is 40.77. In terms of profitability, SWTX's ROE is -0.47%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, SWTX is less volatile compared to KRYS. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check KRYS's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
SWTX vs RXDX Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas RXDX's P/E ratio is -56.47. In terms of profitability, SWTX's ROE is -0.47%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, SWTX is less volatile compared to RXDX. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check RXDX's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
SWTX vs AXSM Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, AXSM has a market cap of 9.4B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while AXSM trades at $182.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas AXSM's P/E ratio is -47.54. In terms of profitability, SWTX's ROE is -0.47%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, SWTX is less volatile compared to AXSM. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check AXSM's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
SWTX vs NUVL Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas NUVL's P/E ratio is -21.79. In terms of profitability, SWTX's ROE is -0.47%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, SWTX is similarly volatile compared to NUVL. This indicates similar risk in terms of short-term price fluctuations for SWTX.Check NUVL's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
SWTX vs ARWR Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, ARWR has a market cap of 9.1B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while ARWR trades at $64.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas ARWR's P/E ratio is -28.80. In terms of profitability, SWTX's ROE is -0.47%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, SWTX is less volatile compared to ARWR. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check ARWR's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
SWTX vs KYMR Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, KYMR has a market cap of 9.1B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while KYMR trades at $110.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas KYMR's P/E ratio is -34.41. In terms of profitability, SWTX's ROE is -0.47%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, SWTX is less volatile compared to KYMR. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check KYMR's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
SWTX vs CRNX Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas CRNX's P/E ratio is -16.86. In terms of profitability, SWTX's ROE is -0.47%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, SWTX is similarly volatile compared to CRNX. This indicates similar risk in terms of short-term price fluctuations for SWTX.Check CRNX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
SWTX vs PTGX Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, PTGX has a market cap of 9B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while PTGX trades at $139.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas PTGX's P/E ratio is 135.14. In terms of profitability, SWTX's ROE is -0.47%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, SWTX is less volatile compared to PTGX. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check PTGX's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
SWTX vs IMGN Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas IMGN's P/E ratio is -111.55. In terms of profitability, SWTX's ROE is -0.47%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, SWTX is less volatile compared to IMGN. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check IMGN's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
SWTX vs BPMC Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas BPMC's P/E ratio is -51.58. In terms of profitability, SWTX's ROE is -0.47%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, SWTX is similarly volatile compared to BPMC. This indicates similar risk in terms of short-term price fluctuations for SWTX.Check BPMC's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
SWTX vs APGE Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas APGE's P/E ratio is -31.19. In terms of profitability, SWTX's ROE is -0.47%, compared to APGE's ROE of -0.30%. Regarding short-term risk, SWTX is similarly volatile compared to APGE. This indicates similar risk in terms of short-term price fluctuations for SWTX.Check APGE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
SWTX vs TGTX Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, TGTX has a market cap of 8.2B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while TGTX trades at $53.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas TGTX's P/E ratio is 19.43. In terms of profitability, SWTX's ROE is -0.47%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, SWTX is less volatile compared to TGTX. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check TGTX's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
SWTX vs CERE Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas CERE's P/E ratio is -16.47. In terms of profitability, SWTX's ROE is -0.47%, compared to CERE's ROE of -0.72%. Regarding short-term risk, SWTX is less volatile compared to CERE. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check CERE's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
SWTX vs CYTK Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, CYTK has a market cap of 8.2B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while CYTK trades at $65.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas CYTK's P/E ratio is -9.09. In terms of profitability, SWTX's ROE is -0.47%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, SWTX is less volatile compared to CYTK. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check CYTK's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
SWTX vs PCVX Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, PCVX has a market cap of 8.1B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while PCVX trades at $56.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas PCVX's P/E ratio is -7.35. In terms of profitability, SWTX's ROE is -0.47%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, SWTX is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check PCVX's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
SWTX vs CAI Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, CAI has a market cap of 8B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while CAI trades at $28.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas CAI's P/E ratio is 79.66. In terms of profitability, SWTX's ROE is -0.47%, compared to CAI's ROE of +0.19%. Regarding short-term risk, SWTX is less volatile compared to CAI. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check CAI's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
SWTX vs PRAX Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, PRAX has a market cap of 8B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while PRAX trades at $286.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas PRAX's P/E ratio is -22.19. In terms of profitability, SWTX's ROE is -0.47%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, SWTX is less volatile compared to PRAX. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check PRAX's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
SWTX vs SYRE Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, SYRE has a market cap of 7.8B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while SYRE trades at $89.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas SYRE's P/E ratio is -46.12. In terms of profitability, SWTX's ROE is -0.47%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, SWTX is less volatile compared to SYRE. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check SYRE's competition here
Metsera, Inc. (NASDAQ: MTSR)
SWTX vs MTSR Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas MTSR's P/E ratio is -23.58. In terms of profitability, SWTX's ROE is -0.47%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, SWTX is less volatile compared to MTSR. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check MTSR's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
SWTX vs IONS Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, IONS has a market cap of 7.3B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while IONS trades at $44.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas IONS's P/E ratio is -13.46. In terms of profitability, SWTX's ROE is -0.47%, compared to IONS's ROE of -1.11%. Regarding short-term risk, SWTX is less volatile compared to IONS. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check IONS's competition here
Abivax S.A. (NASDAQ: ABVX)
SWTX vs ABVX Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, ABVX has a market cap of 7B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while ABVX trades at $95.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas ABVX's P/E ratio is -18.10. In terms of profitability, SWTX's ROE is -0.47%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, SWTX is less volatile compared to ABVX. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check ABVX's competition here
Immunovant, Inc. (NASDAQ: IMVT)
SWTX vs IMVT Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, IMVT has a market cap of 6.9B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while IMVT trades at $33.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas IMVT's P/E ratio is -11.93. In terms of profitability, SWTX's ROE is -0.47%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, SWTX is less volatile compared to IMVT. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check IMVT's competition here
Merus N.V. (NASDAQ: MRUS)
SWTX vs MRUS Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas MRUS's P/E ratio is -17.05. In terms of profitability, SWTX's ROE is -0.47%, compared to MRUS's ROE of -0.46%. Regarding short-term risk, SWTX is similarly volatile compared to MRUS. This indicates similar risk in terms of short-term price fluctuations for SWTX.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
SWTX vs ACLX Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas ACLX's P/E ratio is -28.27. In terms of profitability, SWTX's ROE is -0.47%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, SWTX is less volatile compared to ACLX. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
SWTX vs RETA Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas RETA's P/E ratio is -66.29. In terms of profitability, SWTX's ROE is -0.47%, compared to RETA's ROE of +0.47%. Regarding short-term risk, SWTX is less volatile compared to RETA. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check RETA's competition here
Belite Bio, Inc (NASDAQ: BLTE)
SWTX vs BLTE Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, BLTE has a market cap of 6.5B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while BLTE trades at $162.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas BLTE's P/E ratio is -87.16. In terms of profitability, SWTX's ROE is -0.47%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, SWTX is less volatile compared to BLTE. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check BLTE's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
SWTX vs RYTM Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, RYTM has a market cap of 6.4B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while RYTM trades at $93.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas RYTM's P/E ratio is -30.04. In terms of profitability, SWTX's ROE is -0.47%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, SWTX is less volatile compared to RYTM. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check RYTM's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
SWTX vs IOVA Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, IOVA has a market cap of 6.4B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while IOVA trades at $14.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas IOVA's P/E ratio is -19.49. In terms of profitability, SWTX's ROE is -0.47%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, SWTX is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check IOVA's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
SWTX vs CNTA Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas CNTA's P/E ratio is -22.63. In terms of profitability, SWTX's ROE is -0.47%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, SWTX is similarly volatile compared to CNTA. This indicates similar risk in terms of short-term price fluctuations for SWTX.Check CNTA's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
SWTX vs KOD Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, KOD has a market cap of 6.2B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while KOD trades at $98.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas KOD's P/E ratio is -23.61. In terms of profitability, SWTX's ROE is -0.47%, compared to KOD's ROE of -2.73%. Regarding short-term risk, SWTX is less volatile compared to KOD. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check KOD's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
SWTX vs LGND Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, LGND has a market cap of 6.1B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while LGND trades at $302.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas LGND's P/E ratio is 33.23. In terms of profitability, SWTX's ROE is -0.47%, compared to LGND's ROE of +0.20%. Regarding short-term risk, SWTX is less volatile compared to LGND. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check LGND's competition here
CG Oncology Inc. (NASDAQ: CGON)
SWTX vs CGON Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, CGON has a market cap of 6B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while CGON trades at $68.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas CGON's P/E ratio is -25.41. In terms of profitability, SWTX's ROE is -0.47%, compared to CGON's ROE of -0.25%. Regarding short-term risk, SWTX is less volatile compared to CGON. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check CGON's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
SWTX vs CDTX Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas CDTX's P/E ratio is -19.77. In terms of profitability, SWTX's ROE is -0.47%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, SWTX is similarly volatile compared to CDTX. This indicates similar risk in terms of short-term price fluctuations for SWTX.Check CDTX's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
SWTX vs SRRK Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, SRRK has a market cap of 5.5B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while SRRK trades at $46.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas SRRK's P/E ratio is -13.38. In terms of profitability, SWTX's ROE is -0.47%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, SWTX is less volatile compared to SRRK. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check SRRK's competition here
Abcam plc (NASDAQ: ABCM)
SWTX vs ABCM Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, SWTX's ROE is -0.47%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, SWTX is less volatile compared to ABCM. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
SWTX vs ISEE Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas ISEE's P/E ratio is -22.44. In terms of profitability, SWTX's ROE is -0.47%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, SWTX is less volatile compared to ISEE. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check ISEE's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
SWTX vs COGT Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, COGT has a market cap of 5.4B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while COGT trades at $31.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas COGT's P/E ratio is -14.97. In terms of profitability, SWTX's ROE is -0.47%, compared to COGT's ROE of -0.73%. Regarding short-term risk, SWTX is less volatile compared to COGT. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check COGT's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
SWTX vs PTCT Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, PTCT has a market cap of 5.4B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while PTCT trades at $64.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas PTCT's P/E ratio is -27.52. In terms of profitability, SWTX's ROE is -0.47%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, SWTX is less volatile compared to PTCT. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check PTCT's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
SWTX vs CRSP Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, CRSP has a market cap of 5.3B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while CRSP trades at $55.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas CRSP's P/E ratio is -11.65. In terms of profitability, SWTX's ROE is -0.47%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, SWTX is less volatile compared to CRSP. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check CRSP's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
SWTX vs TVTX Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, TVTX has a market cap of 5.3B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while TVTX trades at $56.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas TVTX's P/E ratio is -126.33. In terms of profitability, SWTX's ROE is -0.47%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, SWTX is less volatile compared to TVTX. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check TVTX's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
SWTX vs APLS Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas APLS's P/E ratio is 38.35. In terms of profitability, SWTX's ROE is -0.47%, compared to APLS's ROE of +0.40%. Regarding short-term risk, SWTX is less volatile compared to APLS. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check APLS's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
SWTX vs MIRM Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, MIRM has a market cap of 5.1B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while MIRM trades at $83.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas MIRM's P/E ratio is -5.77. In terms of profitability, SWTX's ROE is -0.47%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, SWTX is less volatile compared to MIRM. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check MIRM's competition here
Erasca, Inc. (NASDAQ: ERAS)
SWTX vs ERAS Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, ERAS has a market cap of 5.1B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while ERAS trades at $14.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas ERAS's P/E ratio is -15.68. In terms of profitability, SWTX's ROE is -0.47%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, SWTX is less volatile compared to ERAS. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check ERAS's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
SWTX vs ORKA Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, ORKA has a market cap of 5B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while ORKA trades at $83.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas ORKA's P/E ratio is -43.00. In terms of profitability, SWTX's ROE is -0.47%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, SWTX is less volatile compared to ORKA. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check ORKA's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
SWTX vs DFTX Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, DFTX has a market cap of 5B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while DFTX trades at $37.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas DFTX's P/E ratio is N/A. In terms of profitability, SWTX's ROE is -0.47%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, SWTX is less volatile compared to DFTX. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check DFTX's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
SWTX vs DNTH Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, DNTH has a market cap of 4.9B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while DNTH trades at $88.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas DNTH's P/E ratio is -21.28. In terms of profitability, SWTX's ROE is -0.47%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, SWTX is less volatile compared to DNTH. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check DNTH's competition here
Veradermics, Incorporated (NYSE: MANE)
SWTX vs MANE Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, MANE has a market cap of 4.9B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while MANE trades at $117.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas MANE's P/E ratio is -37.34. In terms of profitability, SWTX's ROE is -0.47%, compared to MANE's ROE of -0.38%. Regarding short-term risk, SWTX is less volatile compared to MANE. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check MANE's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
SWTX vs TERN Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas TERN's P/E ratio is -51.41. In terms of profitability, SWTX's ROE is -0.47%, compared to TERN's ROE of -0.20%. Regarding short-term risk, SWTX is less volatile compared to TERN. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check TERN's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
SWTX vs FOLD Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas FOLD's P/E ratio is -161.00. In terms of profitability, SWTX's ROE is -0.47%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, SWTX is similarly volatile compared to FOLD. This indicates similar risk in terms of short-term price fluctuations for SWTX.Check FOLD's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
SWTX vs AKRO Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas AKRO's P/E ratio is -14.57. In terms of profitability, SWTX's ROE is -0.47%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, SWTX is less volatile compared to AKRO. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
SWTX vs ALPN Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas ALPN's P/E ratio is -101.52. In terms of profitability, SWTX's ROE is -0.47%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, SWTX is less volatile compared to ALPN. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check ALPN's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
SWTX vs ADPT Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, ADPT has a market cap of 4.4B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while ADPT trades at $27.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas ADPT's P/E ratio is -66.76. In terms of profitability, SWTX's ROE is -0.47%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, SWTX is less volatile compared to ADPT. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check ADPT's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
SWTX vs EWTX Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, EWTX has a market cap of 4.4B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while EWTX trades at $40.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas EWTX's P/E ratio is -21.88. In terms of profitability, SWTX's ROE is -0.47%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, SWTX is less volatile compared to EWTX. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check EWTX's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
SWTX vs ABCL Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, ABCL has a market cap of 4.2B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while ABCL trades at $13.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas ABCL's P/E ratio is -25.76. In terms of profitability, SWTX's ROE is -0.47%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, SWTX is less volatile compared to ABCL. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check ABCL's competition here
Opthea Limited (NASDAQ: OPT)
SWTX vs OPT Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas OPT's P/E ratio is -1.52. In terms of profitability, SWTX's ROE is -0.47%, compared to OPT's ROE of +1.18%. Regarding short-term risk, SWTX is similarly volatile compared to OPT. This indicates similar risk in terms of short-term price fluctuations for SWTX.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
SWTX vs PRTC Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas PRTC's P/E ratio is -3.78. In terms of profitability, SWTX's ROE is -0.47%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, SWTX is less volatile compared to PRTC. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check PRTC's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
SWTX vs MRTX Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas MRTX's P/E ratio is -4.82. In terms of profitability, SWTX's ROE is -0.47%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, SWTX is less volatile compared to MRTX. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check MRTX's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
SWTX vs RLAY Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, RLAY has a market cap of 4.1B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while RLAY trades at $18.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas RLAY's P/E ratio is -11.78. In terms of profitability, SWTX's ROE is -0.47%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, SWTX is less volatile compared to RLAY. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check RLAY's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
SWTX vs TNGX Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, TNGX has a market cap of 4B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while TNGX trades at $24.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas TNGX's P/E ratio is -29.46. In terms of profitability, SWTX's ROE is -0.47%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, SWTX is less volatile compared to TNGX. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check TNGX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
SWTX vs CPRX Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas CPRX's P/E ratio is 17.49. In terms of profitability, SWTX's ROE is -0.47%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, SWTX is similarly volatile compared to CPRX. This indicates similar risk in terms of short-term price fluctuations for SWTX.Check CPRX's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
SWTX vs XENE Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, XENE has a market cap of 3.8B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while XENE trades at $38.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas XENE's P/E ratio is -8.28. In terms of profitability, SWTX's ROE is -0.47%, compared to XENE's ROE of -0.44%. Regarding short-term risk, SWTX is less volatile compared to XENE. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check XENE's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
SWTX vs RYZB Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas RYZB's P/E ratio is -57.86. In terms of profitability, SWTX's ROE is -0.47%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, SWTX is less volatile compared to RYZB. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check RYZB's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
SWTX vs CBAY Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas CBAY's P/E ratio is -32.81. In terms of profitability, SWTX's ROE is -0.47%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, SWTX is less volatile compared to CBAY. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check CBAY's competition here
Celcuity Inc. (NASDAQ: CELC)
SWTX vs CELC Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, CELC has a market cap of 3.7B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while CELC trades at $75.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas CELC's P/E ratio is -17.47. In terms of profitability, SWTX's ROE is -0.47%, compared to CELC's ROE of -3.51%. Regarding short-term risk, SWTX is less volatile compared to CELC. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check CELC's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
SWTX vs TLX Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, TLX has a market cap of 3.6B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while TLX trades at $10.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas TLX's P/E ratio is 111.90. In terms of profitability, SWTX's ROE is -0.47%, compared to TLX's ROE of +0.07%. Regarding short-term risk, SWTX is less volatile compared to TLX. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check TLX's competition here
IDEAYA Biosciences, Inc. (NASDAQ: IDYA)
SWTX vs IDYA Comparison October 2026
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, SWTX stands at 3.5B. In comparison, IDYA has a market cap of 3.6B. Regarding current trading prices, SWTX is priced at $46.99 on the NASDAQ, while IDYA trades at $37.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
SWTX currently has a P/E ratio of -13.78, whereas IDYA's P/E ratio is -19.49. In terms of profitability, SWTX's ROE is -0.47%, compared to IDYA's ROE of -0.16%. Regarding short-term risk, SWTX is less volatile compared to IDYA. This indicates lower risk in terms of short-term price fluctuations for SWTX.Check IDYA's competition here